DDRE-09. DEVELOPING IDO-PROTACS TO IMPROVE IMMUNOTHERAPEUTIC EFFICACY IN PATIENTS WITH GLIOBLASTOMA

INTRODUCTION: Indoleamine 2,3-dioxygenase 1 (IDO; IDO1) is a rate-limiting enzyme that metabolizes the essential amino acid tryptophan into kynurenine. Recent work by our group has revealed that IDO promotes tumor development and suppresses immune cell functions independent of its enzyme activity. M...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Bollu, Lakshmi, Wainwright, Derek, Zhai, Lijie, Ladomersky, Erik, Lauing, Kristen, Bell, April, Schlitz, Gary
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Drug Discovery, Drug Resistance
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651014/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.254
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky